Edgar Filing: Xenon Pharmaceuticals Inc. - Form 4

Xenon Pharn Form 4 August 02, 2	naceuticals Inc. 016										
									OMB A	PPROVAL	
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549								OMB Number:	3235-0287		
Check thi if no long		STATEMENT OF CHANGES IN BENEFICIAL OWN SECURITIES							Expires:	January 31,	
subject to Section 1 Form 4 o	6. r								Estimated a burden hou response		
Form 5 obligations may continue.Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 19401(b).30(h) of the Investment Company Act of 1940											
(Print or Type F	Responses)										
PIMSTONE SIMON N. Symbo			Symbol	Name and Pharmace			-	5. Relationship of Reporting Person(s) to Issuer			
						с. [A		(Check all applicable)			
(Montl			3. Date of Earliest Transaction (Month/Day/Year)					X Director 10% Owner X Officer (give title Other (specify below) President & CEO			
				7/29/2016							
(Street) 4. If Amer			endment, Date Original				6. Individual or Joint/Group Filing(Check				
Filed(Mon			onth/Day/Year)				Applicable Line) _X_ Form filed by One Reporting Person				
BURNABY, A1 V5G 4W8 Form filed by More than One Reporting Person Person											
(City)	(State)	(Zip)	Table	e I - Non-D	erivative S	Securi	ties Acq	uired, Disposed of	, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)2. Transaction Date (Month/Day/Year)2A. De Execution any (Month				3. 4. Securities Acquired Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8) (A)			l of (D)	Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Indirect	
				Code V	Amount	or (D)	Price	Transaction(s) (Instr. 3 and 4)			
Common	07/29/2016			M		A	\$ 3.3	216,550	D		
Shares					,		(1) •				
Common Shares	07/29/2016			F	4,703	D	\$ 7.46 (2)	211,847	D		
Common Shares								16,460	Ι	By Spouse	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)

Edgar Filing: Xenon Pharmaceuticals Inc. - Form 4

required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. 5. Number of TransactiorDerivative Code Securities (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		Expiration Date		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8 D S (1
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (Right to Buy)	\$ 3.3 <u>(1)</u>	07/29/2016	М	12,345	(3)	07/31/2016	Common Shares	12,345	

Reporting Owners

Reporting Owner Name / Address		Relationships						
	Director	10% Owner	Officer	Other				
PIMSTONE SIMON N. C/O XENON PHARMACEUTICALS 200 - 3650 GILMORE WAY BURNABY, A1 V5G 4W8	INC X		President & CEO					
Signatures								
/s/ Joanne Smartt, Attorney-in-fact	08/02/2016							
**Signature of Reporting Person	Date							

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The exercise price was converted from \$3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise.
- (2) Represents the closing price of the Company's common shares on July 28, 2016, converted to a Canadian dollar amount for purposes of net settlement calculations.
- (3) The shares subject to the option fully vested on August 1, 2010.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.